Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Sponsor
Fundación GECP
Study ID
NCT03836066
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multi-center phase II clinical trial of atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastasic high-intermediate tumour mutation burden selected NSCLC patients. 102 patients will be enrolled in this trial to examine the efficacy of this combination measured by progression free survival according to response evaluation Criteria in solid tumours (RECIST) version 1.1.

Key Dates

Start date
May 15, 2019
Status verified
Nov 2025
Primary completion
Oct 21, 2024
Completion
Oct 21, 2024

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Atezolizumab plus Bevacizumab arm
    1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.

Primary Outcome Measure

Efficacy of Atezolizumab in Combination With Bevacizumab - PFS [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ]

Related coverage on Hipa.ai

Related Studies